Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia.
Aged
B-Lymphocytes
/ metabolism
Cell Proliferation
/ genetics
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ genetics
Lymphocyte Activation
/ genetics
Male
Middle Aged
Proteome
/ genetics
Proteomics
/ methods
Receptors, Antigen, B-Cell
/ genetics
Signal Transduction
/ genetics
Transcription, Genetic
/ genetics
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
01
10
2020
accepted:
09
03
2021
revised:
21
02
2021
pubmed:
10
4
2021
medline:
16
6
2021
entrez:
9
4
2021
Statut:
ppublish
Résumé
B-cell receptor (BCR) signaling is crucial for the pathophysiology of most mature B-cell lymphomas/leukemias and has emerged as a therapeutic target whose effectiveness remains limited by the occurrence of mutations. Therefore, deciphering the cellular program activated downstream this pathway has become of paramount importance for the development of innovative therapies. Using an original ex vivo model of BCR-induced proliferation of chronic lymphocytic leukemia cells, we generated 108 temporal transcriptional and proteomic profiles from 1 h up to 4 days after BCR activation. This dataset revealed a structured temporal response composed of 13,065 transcripts and 4027 proteins, comprising a leukemic proliferative signature consisting of 430 genes and 374 proteins. Mathematical modeling of this complex cellular response further highlighted a transcriptional network driven by 14 early genes linked to proteins involved in cell proliferation. This group includes expected genes (EGR1/2, NF-kB) and genes involved in NF-kB signaling modulation (TANK, ROHF) and immune evasion (KMO, IL4I1) that have not yet been associated with leukemic cells proliferation. Our study unveils the BCR-activated proliferative genetic program in primary leukemic cells. This approach combining temporal measurements with modeling allows identifying new putative targets for innovative therapy of lymphoid malignancies and also cancers dependent on ligand-receptor interactions.
Identifiants
pubmed: 33833385
doi: 10.1038/s41375-021-01221-5
pii: 10.1038/s41375-021-01221-5
pmc: PMC8102193
doi:
Substances chimiques
Proteome
0
Receptors, Antigen, B-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1463-1474Références
Bioinformatics. 2014 Feb 15;30(4):571-3
pubmed: 24307703
Bioinformatics. 2015 May 1;31(9):1420-7
pubmed: 25563332
PLoS One. 2012;7(8):e43432
pubmed: 22952681
Cell. 2011 Mar 18;144(6):860-3
pubmed: 21414478
PLoS One. 2013;8(4):e60275
pubmed: 23560086
Bioinformatics. 2013 Sep 1;29(17):2146-52
pubmed: 23821648
J Clin Invest. 1997 Dec 15;100(12):2961-9
pubmed: 9399941
Ann Hematol. 2013 Dec;92(12):1603-9
pubmed: 23892923
Br J Haematol. 2005 May;129(4):531-3
pubmed: 15877735
Mol Cell Proteomics. 2010 Feb;9(2):271-84
pubmed: 19955083
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Br J Haematol. 2003 Nov;123(3):380-8
pubmed: 14616995
Blood. 2011 Jan 13;117(2):563-74
pubmed: 20940416
EMBO J. 1999 Dec 1;18(23):6694-704
pubmed: 10581243
Cancer Res. 2007 Feb 15;67(4):1812-22
pubmed: 17308124
Cytometry B Clin Cytom. 2006 Jul 15;70(4):309-14
pubmed: 16906588
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):459-64
pubmed: 23267079
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
PLoS One. 2008 May 07;3(5):e2097
pubmed: 18461186
J Exp Med. 2004 Aug 16;200(4):519-25
pubmed: 15314077
Nat Cell Biol. 2012 Jun 03;14(7):677-85
pubmed: 22660413
Database (Oxford). 2015 Sep 30;2015:
pubmed: 26424082
Blood. 2002 Jan 1;99(1):232-7
pubmed: 11756176
Blood. 2013 Oct 24;122(17):3010-9
pubmed: 24014238
Blood. 2007 Jul 1;110(1):220-7
pubmed: 17356132
Sci Rep. 2019 Jan 24;9(1):701
pubmed: 30679590
Int Immunol. 2000 Apr;12(4):517-26
pubmed: 10744653
Nat Immunol. 2009 Mar;10(3):281-8
pubmed: 19198593
Mol Cell Proteomics. 2016 Feb;15(2):657-68
pubmed: 26566788
Nat Rev Immunol. 2002 Dec;2(12):945-56
pubmed: 12461567
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):13000-13005
pubmed: 29180417
PLoS One. 2012;7(3):e34515
pubmed: 22479638
Cells. 2019 Jun 26;8(7):
pubmed: 31248017
J Immunol. 2018 Feb 1;200(3):1027-1038
pubmed: 29288206
Blood. 2008 Aug 1;112(3):782-92
pubmed: 18487510
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Bioinformatics. 2021 May 5;37(5):659-668
pubmed: 33016991
PLoS One. 2019 Apr 18;14(4):e0215746
pubmed: 30998758
Blood. 2007 Mar 1;109(5):2032-9
pubmed: 17038529
Blood. 2005 Aug 15;106(4):1382-91
pubmed: 15890690
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Blood. 2011 Oct 20;118(16):4313-20
pubmed: 21816833
Leukemia. 2011 Jul;25(7):1080-94
pubmed: 21494257
Oncotarget. 2016 Dec 6;7(49):80175-80189
pubmed: 27863394
Immunol Cell Biol. 2003 Aug;81(4):247-65
pubmed: 12848846
Nat Immunol. 2009 Sep;10(9):965-72
pubmed: 19668221
Annu Rev Immunol. 2012;30:565-610
pubmed: 22224767
Cell. 2011 Mar 18;144(6):886-96
pubmed: 21414481
Blood. 2007 May 1;109(9):3989-97
pubmed: 17234734